Leal Therapeutics Closes $30 Million Series A Extension and Launches Schizophrenia Trial
Leal Therapeutics announced a $30 million second close of its Series A financing and initiated a Phase 1b/2a trial of LTX-001 in adults with schizophrenia, with initial data expected by year-end.
The financing follows the appointment of a new Chief Medical Officer and Chief Business Officer earlier this year.
